Evaluation of Midazolam as an Intravenous Induction Agent for General Anaesthesia-Comparison with Thiopentone

Cecilia Lalramhlui¹, Lalnun Mawii Sailo²

ABSTRACT

Introduction: Midazolam, a water-soluble benzodiazepine, is non-irritant on intravenous injection and has a shorter duration of action than diazepam. In this research, we evaluated the induction time achieved with midazolam and compared with thiopentone. We also observed the hemodynamic effects following induction with midazolam and thiopentone. In the current study, we also studied undesirable or unwanted effects of the two drugs.

Material and methods: The present study was conducted at Civil Hospital, Aizawl Mizoram in the Department of Anaesthesiology and Critical Care. The study was conducted between November 2018 to October 2019. A clinical study was carried out in hundred patients with a physical status of ASA I and ASA II patients, patients between 20-50 years of age and weight 45-70 kg were selected and were divided into two groups each group consisting of fifty patients. Group A – Midazolam (0.2mg/kg) and Group B – Thiopentone (5mg/kg). A routine preanaesthetic check-up was carried out before the operation. The procedure of anaesthesia to be given was explained to the patients and written informed consent was taken accordingly.

Results: The mean age (in years) of the midazolam group was 35.54 ± 8.5 and it was 34.06 ± 10.2 in the thiopentone group. We found a statistically significant difference of weight, spontaneous closure of eye, Loss of lid reflex between both the groups. Patient Good acceptance was good in 16 (66.67%) participants in midazolam and 8 (33.33%) participants in the thiopentone group.

Conclusion: We conclude that midazolam is a satisfactory substitute to thiopentone.

Keywords: Midazolam, Thiopentone, General Anaesthesia, Induction Agent

INTRODUCTION

In the intensive care unit (ICU) therapy sedation is considered as a backbone due to its requirement by >85% of patients. Sedative drugs are used for assisting tolerance of endotracheal intubation, to manage agitation, mechanical ventilation, and invasive procedures. Back in time during 1656, Daniel Johann Major and Percival Christopher Wren first experimented with IV administration using a goose quill and bladder to inject wine into a dog’s vein by which Intravenous (IV) anaesthesia can be traced back. As intravenous anaesthetics, ultra-short-acting barbiturates were the first universally accepted drugs. The majority of knowledge about intravenous anaesthesia was generated through their use. Anaesthesia through intravenous agents is a clinical state in which several behavioural endpoints occur due to a structurally distinct group of drugs. Particular membrane proteins own peculiar binding sites that interact with injectable medications presently used for clinical anaesthesia.

Midazolam, a water-soluble benzodiazepine, is non-irritant on intravenous injection and possesses a shorter duration of action than diazepam. When compared with diazepam administered in an organic solvent water solubility reduces venous thrombosis and pain on injection. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. Currently, in dentistry and endoscopic procedures, it has been used mainly by the intravenous route for sedation as an addition to local anaesthetic techniques. Midazolam is a worthy premedical for regional or general anaesthesia. Induction of anaesthesia with midazolam alone is somewhat unpredictable; opiate pre-treatment makes induction more consistent.

Since 1935 thiopentone sodium has been in use. It is a benchmark for comparing all other induction agents. Its use is associated with the lowest occurrence of complications and is possibly the most extensively used induction agent. Thiopental, the dithiobarbiturate analogue of the oxybarbiturate pentobarbital, was the most frequently used intravenous barbiturate in medicine and is prototypic of the group. Thiopental is defined as ultrashort-acting; it induces anaesthesia of only short duration after a small dose is administered. If a patient is maintained under prolonged anaesthesia, however, by successive injections of thiopental, the period of subsequent continuing narcosis is also prolonged; it no longer behaves as an ultra-short-acting drug. This characteristic of thiopental has been ascribed to production and accumulation in the body of less active metabolic transformation products which have a long duration of action. This characteristic of drug action is one of its chief limitations and has restricted its un-supplemented
use as a rule to surgical and obstetric procedures of relatively short duration. In this research, we evaluated the induction time achieved with midazolam and compared with thiopentone. We also observed the hemodynamic effects following induction with midazolam and thiopentone. In the current study, we also studied undesirable or unwanted effects of the two drugs.

**MATERIAL AND METHODS**

The present study was conducted at Civil Hospital, Aizawl Mizoram in the department of Anaesthesiology and Critical Care after institutional ethical approval. The study was conducted between November 2018 to October 2019. A clinical study was carried out in hundred patients with a physical status of ASA I and ASA II patients, patients between 20-50 years of age and weight 45-70 kg were selected and were divided into two groups each consisting of fifty patients. Group A – Midazolam (0.2mg/kg) and Group B – Thiopentone (5mg/kg).

Patients with neurological, renal, hepatic cardiovascular metabolic or endocrine dysfunctions, also pregnant and breast-feeding women were excluded from the study.

**Pre anaesthetic preparation**

A routine preanaesthetic check-up was carried out before the operation. The procedure of anaesthesia to be given was explained to the patients and written informed consent was taken accordingly. Parameters including Chief complaint, history of present as well as past illness and treatment, previous experience to any anaesthetic agent, Personal history, history of habits, history of any drug allergy or drug therapy, menstrual history in females were recorded.

**Preparation of the patient**

Patients were kept nil orally overnight. Oral diazepam, 0.2 mg/kg, was given the night before. Premedication with injection atropine 0.6mg promethazine injection 0.5 mg/kg and pethidine 1mg/kg intramuscularly were given one hour before the induction of anaesthesia.

**Induction and intraoperative period**

Pre-oxygenation was done for three minutes. Pre induction recordings of blood pressure, pulse and respiration rate and were done, and induction was done with midazolam 0.2 mg/kg or thiopentone 5mg/kg over a period of 30 seconds. If the palpebral reflex was present for 60 seconds after the first dose, the second dose was given which is 50% of the first dose over a period of 15 seconds. Induction time which was taken as timing in second from induction to spontaneous closure of eyes and loss of lid reflex was observed. Recordings of blood pressure, pulse and respiratory rates at one-minute intervals for three minutes were done. Suxamethonium 1.5 mg/kg was used for tracheal intubation. Anaesthesia was maintained with oxygen, nitrous oxide, and halothane, pancuronium 0.1 mg/kg for muscle relaxation and controlled ventilation. Patients were extubated, suction was done and oxygen inhalational was given for 5 minutes or till the patients recover.

**Post-operative period**

Nausea recordings were done by direct questioning of the patient. Vomiting is recorded by a direct examination of the patients. The incidence of thrombophlebitis was recorded. The patient’s acceptance with particulars reference to the induction phase was recorded. The information for each patient was elicited on a predesigned proforma. For analysis purpose information were transferred to a master chart, then fitted to the computer. With the help of SPSS, data were analysed by using a t-test, f-test and x2-test wherever found suitable and necessary, and the interpretation was made accordingly.

**RESULTS**

In the midazolam group, 16 (45.71%) participants were male and the remaining 19 (54.29%) participants were female. In the thiopentone group, 34 (52.31%) participants were male and the remaining 31 (47.69%) participants were female. The difference in the proportion of gender between the group was statistically not significant (P-value 0.529).

The mean age (in years) of the midazolam group was 35.54 ± 8.5 and it was 34.06 ± 10.2 in the thiopentone group. The mean difference between the two groups was statistically not significant (P-value 0.465). The mean weight (in kg) of the midazolam group was 53.80 ± 4.9 and it was 53.88 ± 2.6 in the thiopentone group. The mean difference between the two groups was statistically significant (P-value <0.001). The mean spontaneous closure of the eyes of the midazolam group was 77.58±5.52 and it was 51.98±3.35 in the thiopentone group. The mean difference between the two groups was statistically significant (P-value <0.001). The mean loss of the lid reflex of the midazolam group was 98.78±6.08 and it was 66.66±3.71 in the thiopentone group. The mean difference between the two groups was statistically significant (P-value <0.001) (table-1).

There was no statistically significant difference between two groups in systolic blood pressure pre-induction and 2 mints time periods. The mean systolic blood pressure 1st mints of the midazolam group was 116.64 ± 11.62 and it was 110.00 ± 12.16 in the thiopentone group. The mean difference between the two groups was statistically significant (P-value 0.009). The mean systolic blood pressure 3mints of the midazolam group was 112.36 ± 1.39 and it was 108.24 ± 9.74 in the thiopentone group. The mean difference between the two groups was statistically significant (P-value 0.014).

There was no statistically significant difference between two groups in diastolic blood pressure pre-induction, 1 min, 2 mints and 3 mints follow up time periods. (Table 2)

There was no statistically significant difference between two groups in pulse rate pre-induction, 1 min, 2 mints, and 3 mints follow up time periods. There was no statistically significant difference between two groups in respiratory rate pre-induction, 1 min, 2 mints and 3 mints follow up time periods. (Table 3)

In the Midazolam group, 13 (72.22%) participants had nausea, 3 (16.67%) participants had vomiting and 2 (11.11%) participants had thrombophlebitis. In the thiopentone group, 21 (65.63%) participants had nausea, 5 (15.63%)...
### Table 1: Comparison of background variables between the study group (N=100)

| Parameter                  | Study group          | P-value |
|----------------------------|----------------------|---------|
|                            | Midazolam (N=35)     |         |
|                            | Thiopentone (N=65)   |         |
| Gender (N(%))              |                      |         |
| Male                       | 16 (45.71%)          |         |
|                           | 34 (52.31%)          | 0.529   |
| Female                     | 19 (54.29%)          |         |
|                           | 31 (47.69%)          |         |
| Age (Mean ± SD)            | 35.54 ± 8.5          |         |
|                           | 34.06 ± 10.2         | 0.465   |
| Weight (Mean ± SD)         | 53.80 ± 4.9          |         |
|                           | 53.88 ± 2.6          | <0.001  |
| Induction time (seconds)   |                      |         |
| Spontaneous closure of eyes| 77.58±5.52           |         |
|                           | 51.98±3.35           | <0.001  |
| Loss of lid reflex         | 98.78±6.08           |         |
|                           | 66.66±3.71           | <0.001  |

### Table 2: Comparison of blood pressure between the study group over four stages of time interval (minutes) (N=100)

| Time interval minutes | Midazolam | Thiopentone | t-Value | P-Value |
|-----------------------|-----------|-------------|---------|---------|
|                       | Mean ± S. D | Mean ± S. D |         |         |
| Systolic Pre-induction| 122.40 ±11.74| 120 ± 10.59 | 1.46    | 0.300   |
| 1st Min               | 116.64 ± 11.62| 110.00 ± 12.16| 0.69  | 0.009   |
| 2nd Min               | 109.96 ± 18.47| 108.44 ± 9.94| 0.51   | 0.593   |
| 3rd Min               | 112.36 ± 1.39| 108.24 ± 9.74| 1.96   | 0.014   |
| Diastolic Pre-induction| 79.08 ± 8.18 | 77.60 ± 7.43 | 0.94   | 0.361   |
| 1st Min               | 76.04 ± 8.18 | 74.96 ± 6.91 | 1.32   | 0.486   |
| 2nd Min               | 77.04 ± 8.51 | 74.72 ± 6.86 | 1.50   | 0.141   |
| 3rd Min               | 77.04 ± 1.39 | 74.92 ± 7.11 | 1.36   | 0.085   |

### Table 3: Comparison of pulse rate and respiratory between study group over for stages of time interval (minutes) (N=100)

| Time interval minutes | Midazolam | Thiopentone | t-Value | P-Value |
|-----------------------|-----------|-------------|---------|---------|
|                       | Mean ± S. D | Mean ± S. D |         |         |
| Pulse rate Pre-induction| 88.86 ±11.31| 86.70 ± 11.39| 0.95   | 0.367   |
| 1st minute            | 86.22 ± 9.92| 82.78 ± 15.50| 1.32   | 0.238   |
| 2nd minute            | 86.46 ± 10.08| 87.06 ± 10.56| 0.29   | 0.784   |
| 3rd minute            | 86.40 ± 10.11| 87.98 ± 10.35| 0.77   | 0.465   |
| Respiratory rate Pre-induction| 17.56 ± 1.34| 17.14 ± 1.56 | 1.44   | 0.181   |
| 1st minute            | 16.5 ± 1.22 | 16.24 ± 1.47 | 0.19   | 0.374   |
| 2nd minute            | 16.68 ± 1.25| 17.02 ± 1.51 | 1.25   | 0.257   |
| 3rd minute            | 16.86 ± 1.30| 18.97 ± 7.15 | 2.13   | 0.087   |

### Table 4: Variation of complication between midazolam and thiopentone

| Complication       | Study group          | Chi square | P-value |
|--------------------|----------------------|------------|---------|
|                    | Midazolam (N=18)     |            |         |
|                    | Thiopentone (N=32)   |            |         |
| Nausea             | 13 (72.22%)          | 21 (65.63%)| 0.502   | 0.778   |
| Vomiting           | 3 (16.67%)           | 5 (15.63%) |          |         |
| Thrombophlebitis   | 2 (11.11%)           | 6 (18.75%) |          |         |

### Table 5: Variation of patient acceptances between midazolam and thiopentone

| Patient Acceptances | Study group          |         |
|--------------------|----------------------|---------|
|                    | Midazolam            | Thiopentone |
| Good (N=24)        | 16 (66.67%)          | 8 (33.33%)   |
| Satisfactory (N=70)| 34 (48.57%)          | 36 (51.43%)  |
| Bad (N=2)          | 0 (0%)               | 2 (100%)    |
| Could Not Say (N=4)| 0 (0%)               | 4 (100%)    |

The difference in the proportion of complications between the study group was statistically not significant (P-value 0.778). (Table 4) Out of 24 participants with good patient acceptance, 16 (66.67%) participants had midazolam and 8 (33.33%) participants had thiopentone. Out of 70 participants with Satisfactory patient acceptances, 34 (48.57%) participants had midazolam and 36 (51.43%) participants had thiopentone. Out of 2 participants with bad patient acceptances, all of them 2 (100%) participants had thiopentone only. Out of 4 participants with could not say patient acceptances, all of them.
DISCUSSION

Any anaesthetic induction agent for day surgery should guarantee a smooth induction, immediate functional recovery with minimal postoperative sequelae and a rapid return to street fitness. Thioptene is still justifiably famous for inpatient procedures because of the smooth induction offered and in spite of the drug’s known slow metabolism many anaesthetists continue to use this agent for day cases.

Midazolam is a benzodiazepine and its clinical effects are sedation, motion control and anxiolytic. Its initial IV sedative dose is 0.05–0.1 mg/kg or 1 mg and then titrated to a max dose of 5 mg. As IV form, it has an onset of action near 2–3 minutes and the duration of sedation is 45–60 minutes. In major surgery, midazolam is an alternative to thiopental for induction of anaesthesia in spite of its slow, variable induction time. Its advantages include excellent cardiovascular stability, transient and mild respiratory depression, low frequency of venous irritation, production of anterograde amnesia and short duration of action in comparison with other benzodiazepines.

Induction involves the transition from an awake conscious state with intact productive reflexes to an unconscious state. Induction is accomplished when there is unresponsiveness to command and loss of eyelash reflexes. In the present study, we evaluated midazolam as an agent for induction and compared its effects with thiopentone. After assessing gender, age and height in we found no significant difference among both the groups in these variables. We observed female predominance over the male in both groups. It was reported that induction time (second) for spontaneous closure of eyes and Loss of lid reflex was highly significant and less in the thiopentone group compared to the midazolam group. Similarly, Jensen, S et al, in their study found that mean induction time was significantly shorter with thiopentone than with midazolam.

The current research showed a significant fall in systolic blood pressure between 1st to 3rd minute. We observed a significant fall of diastolic pressure from pre-induction to 2nd minute of post-induction in the thiopentone group otherwise no significant fall of diastolic pressure was observed. Lebowitz, PW et al in their research concluded that Midazolam is, then, as acceptable for induction of anaesthesia as thiopentone from a hemodynamic point of view in ASA. class I and II patients. Results of another study showed in the thiopentone group, intubation caused a mean rise in systolic arterial pressure from 141 to 193 mmHg (p < 0.0005) and in the heart rate-systolic pressure product from 11101 to 21763 (p< 0.005 in each case) and were relatively transient and returned to control values within 5 minutes.

We found no significant difference in variation of pulse rate between both the groups. In a study the mean heart rate-systolic pressure products (Mean± SD) for thiopentone were: control 7539±584; at 2.5min 8359±783; at 5min 8010±718; at 10 min 7819±974. For midazolam, these values were 7312 ±542, 7 584 ±645, 6327 ± 573 and 6474 ± 772 respectively. None of the changes was statistically significant, either within each group or between groups.

A study was done by Jensen,S et al found that the Mean (± SD) heart rate in the midazolam group was 70.9 ±9.6 beat min⁻¹ before induction and this increased to 77.4± 11.4 beatsmin⁻¹ 3min after the administration of the drug. Baseline means (± SD) heart rate in the thiopentone group was 69.0 ± 11.0 beat min⁻¹ which increased 3min after injection to 75.7± 11.6 beat min⁻¹. In the midazolam group, there was a highly significant fall in respiratory rate at 1st and 2nd minute and significant fall at 3rd minute. In the thiopentone group, a highly significant fall was observed at 1st minute. Patients showed a decrease in mean respiratory rate from 13.7 breaths/min to 12.8 breaths/ min two minutes after injection of midazolam. When midazolam is administered intravenously for induction of general anaesthesia, respiratory depression occurs through a marked decrease in the ventilatory response to carbon dioxide.

Our study showed the lower post-operative incidence of nausea and vomiting was observed in midazolam compared to thiopentone with incidence thrombophlebitis was found more in thiopentone groups Study conducted by Abraham, J et al found postoperative nausea, vomiting and thrombophlebitis were significantly low with midazolam. The present study revealed that the midazolam group had higher patient acceptance than the thiopentone group. Our results agreed with Abraham, J et al, and Reves, JG et al, as in their study patient acceptance was more for the midazolam group.

CONCLUSION

The present study results showcased that as compared to thiopentone longer time was taken by midazolam to induce anaesthesia. We could observe a significant fall of systolic pressure and respiratory rate in both groups but in diastolic pressure, no significant fall was noted. Midazolam showed less incidence of nausea, vomiting and thrombophlebitis. Overall patient acceptance was higher in the midazolam group. We conclude that midazolam is a satisfactory substitute to thiopentone.

ACKNOWLEDGMENTS

We acknowledge the technical support in data entry, analysis and manuscript editing by “Evidencian Research Associates.”

REFERENCE

1. Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. Crit Care Med. 2007;35:393-401.
2. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263-306.
3. Jarman R. History of intravenous anaesthesia with ten years' experience in the use of pentothal sodium.
Lalramhlui, et al. Midazolam as an Intravenous Induction Agent for General Anaesthesia

International Journal of Contemporary Medical Research
Section: Anesthesiology
ISSN (Online): 2393-915X; (Print): 2454-7379   | ICV: 98.46 | Volume 7 | Issue 1 | January 2020

4. Dowd FJ, Johnson B, Mariotti A. Pharmacology and Therapeutics for Dentistry. 7th ed: Elsevier; 2016. 864 p.
5. Garcia PS, Whalin MK, Sebel PS. 10 - Pharmacology of Intravenous Anesthetics. Foundations and Clinical Application. 2nd ed: Elsevier; 2019. p. 193-216.
6. Hegarty JE, Dundee JW. Sequelae after the intravenous injection of three benzodiazepines—diazepam, lorazepam, and flunitrazepam. Br Med J. 1977;2:1384-5.
7. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs. 1984;28:519-43.
8. Khanderia U, Pandit SK. Use of midazolam hydrochloride in anesthesia. Clin Pharm. 1987;6:533-47.
9. Koshy TA, Mahabala TH, Srikantu J, Sanmathi S. Thiopentone-midazolam mixture as an induction agent for general anesthesia on 'In-Patients'. Indian J Anaesth. 2003;47:129-33.
10. Brodie BB, Burns J, Lief PA, Papper E. Intravenous anesthetics; new concepts. I. Experimental aspects. Curr Res Anesth Analg. 1952;31:145-7.
11. Ogg TW. Use of anaesthesia. Implications of day-case surgery and anaesthesia. Br Med J. 1980;281:212-4.
12. Morgan DJ, Blackman GL, Paull JD, Wolf LJ. Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. Anesthesiology. 1981;54:468-73.
13. Roberts JR, Custalow CB, Thomsen Tw. Roberts and Hedges’ Clinical Procedures in Emergency Medicine. In: Hedges JR, editor. 6th ed: Elsevier Saunders; 2013. p. 1560.
14. Kanto JH. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy. 1985;5:138-55.
15. Abraham J, Kaur B. Evaluation of midazolam as an Intravenous Induction Agent for General Anaesthesia. Indian J Anaesth. 1997;41:34-7.
16. Jensen S, Schou-Olesen A, Hütte M. Use of midazolam as an induction agent: comparison with thiopentone. Br J Anaesth. 1982;54:605-7.
17. Lebowitz PW, Cote ME, Daniels AL, Ramsey FM, Martyn JA, Teplick RS, et al. Comparative cardiovascular effects of midazolam and thiopental in healthy patients. Anesth Analg. 1982;61:771-5.
18. Boralessa H, Senior DF, Whitwam JG. Cardiovascular response to intubation. A comparative study of thiopentone and midazolam. Anaesthesia. 1983;38:623-7.
19. Al-Khudhairi D, Whitwam JG, Chakrabarti MK, Askitopoulou H, Grundy EM, Powrie S. Haemodynamic effects of midazolam and thiopentone during induction of anaesthesia for coronary artery surgery. Br J Anaesth. 1982;54:831-5.
20. Baber R, Hobbes A, Munro IA, Purcell G, Binsted R. Midazolam as an intravenous induction agent for general anaesthesia: a clinical trial. Anaesth Intensive Care. 1982;10:29-35.

21. Gross JB, Zebrowski ME, Carel WD, Gardner S, Smith TC. Time course of ventilatory depression after thiopental and midazolam in normal subjects and in patients with chronic obstructive pulmonary disease. Anesthesiology. 1983;58:540-4.
22. Reves J, Vinik R, Hirschfield A, Holcomb C, Strong S. Midazolam compared with thiopentone as a hypnotic component in balanced anaesthesia: a randomized, double-blind study. Can Anaesth Soc J. 1979;26:42-9.

Submit: 21-12-2019; Accepted: 20-01-2020; Published: 29-01-2020